<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Communidade:</title>
  <link rel="alternate" href="https://ri.ufs.br/jspui/handle/riufs/2414" />
  <subtitle />
  <id>https://ri.ufs.br/jspui/handle/riufs/2414</id>
  <updated>2026-04-27T02:09:07Z</updated>
  <dc:date>2026-04-27T02:09:07Z</dc:date>
  <entry>
    <title>Perfil clínico-neurofisiológico da dor em pessoas com doença de Parkinson: estudo observacional transversal</title>
    <link rel="alternate" href="https://ri.ufs.br/jspui/handle/riufs/24714" />
    <author>
      <name>Santos, Annanda Oliveira</name>
    </author>
    <id>https://ri.ufs.br/jspui/handle/riufs/24714</id>
    <updated>2026-03-09T13:27:07Z</updated>
    <published>2025-01-15T00:00:00Z</published>
    <summary type="text">Título: Perfil clínico-neurofisiológico da dor em pessoas com doença de Parkinson: estudo observacional transversal
Autor(es): Santos, Annanda Oliveira
Abstract: Introduction: Parkinson's disease (PD) is a chronic, progressive neurodegenerative condition characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway and the presence of Lewy bodies, which result from misfolded α-synuclein proteins located in the dopaminergic presynaptic membrane within basal ganglia. The role of pain in PD is debated, as it may be a precursor, concurrent, or secondary symptom. Pain, whether acute or chronic, is complex and challenging in clinical management. Objective: To identify the characteristics of pain in PD and to explore its physiological mechanisms through qualitative sensory tests (QSTs). Materials and Methods: This cross-sectional epidemiological study (CAAE: 64807417.6.0000.5546) involved 33 volunteers with clinically diagnosed PD (20 men, age 58.75 ± 5.16 years; 13 women, age 65.92 ± 7.70 years). Variables analyzed included pain intensity, incidence, and impact, alongside peripheral sensory thresholds, primary and secondary hyperalgesia, ascending and descending nerve function, and thermal latency. Statistical analyses were conducted using SPSS 30.0 and GraphPad Prism 8.0, with significance set at p≤0.05. Tests included Shapiro-Wilk for normality, Mann-Whitney U, Wilcoxon, and one-way repeated measures ANOVA with Bonferroni post-hoc corrections. Results: Most participants reported moderate to severe pain in the last week, with a maximum pain intensity of 6.15 and an average of 3.61. Men reported higher average and minimum pain intensity compared to women, and pain during crises was significantly higher than at rest (p&lt;0.001). Thermal and pain sensitivity testing revealed potential deficits in sensory accommodation, with only six volunteers enduring the maximum time for thermal stimulus, showing an average tolerance of 46.06 seconds. A total of 88 distinct pain sites were identified, highlighting pain’s significant impact on PD and suggesting sensory modulation deficits related to the condition. Conclusion: People with PD have associated chronic pain, with deficits in the excitatory and inhibitory pain pathways. In addition, pain perception is increased, corroborating the findings of chronification.</summary>
    <dc:date>2025-01-15T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Avaliação citotóxica de derivados glicosídicos da lausona em linhagens tumorais</title>
    <link rel="alternate" href="https://ri.ufs.br/jspui/handle/riufs/24713" />
    <author>
      <name>Sousa, Rauan Cruz de</name>
    </author>
    <id>https://ri.ufs.br/jspui/handle/riufs/24713</id>
    <updated>2026-03-09T13:11:27Z</updated>
    <published>2025-07-21T00:00:00Z</published>
    <summary type="text">Título: Avaliação citotóxica de derivados glicosídicos da lausona em linhagens tumorais
Autor(es): Sousa, Rauan Cruz de
Abstract: Cancer is a disease characterized by the abnormal growth of cells that can invade other tissues and spread to other organs, representing a major public health issue. One of the main challenges in cancer treatment is the low selectivity of the chemotherapeutic agents currently used, highlighting the need to investigate new compounds. Lawsone, a plant-derived product, has shown cytotoxic effects in different tumor cell lines, and chemical modifications to its structure can lead to more potent derivatives. Additionally, anomeric isomer derivatives exhibit similar chemical structures, differing only in the orientation of the anomeric carbon, which may influence their biological properties. Therefore, the aim of this study was to evaluate the cytotoxic activity of two anomeric derivatives of lawsone, APSO-5 and APSO-19, in lung carcinoma (A549), melanoma (B16-F10), and glioma (C6) cell lines. The cytotoxicity of the lawsone derivatives, as well as of lawsone itself, was assessed using the Sulforhodamine B assay in the tumor cell lines to determine the IC50 and select the most responsive cell line for subsequent experiments. The results showed that both compounds exhibited cytotoxic effects in all tested cell lines, with IC50 values below 12 μM. The A549 cell line was selected for further experiments, as lung carcinoma is the most prevalent and deadly type of cancer, making the identification of promising therapeutic compounds particularly relevant. The clonogenic assay demonstrated that both compounds reduced colony formation in A549 cells. Furthermore, APSO-19 was found to inhibit cell migration after 24 hours of treatment. Fluorescence assays using DAPI and Phalloidin/FITC revealed morphological changes in A549 cells treated with the derivatives, such as cytoplasmic shrinkage, cell rounding, and the presence of apoptotic bodies. It was also observed that higher concentrations of APSO-19 induced ROS production in A549 cells. Finally, none of the studied compounds showed toxicity toward human erythrocytes. In conclusion, the anomeric glycosidic derivatives of lawsone demonstrated strong cytotoxic effects in the tested cell lines and exhibited distinct biological activities, with APSO-19 showing greater ROS induction and inhibition of migration capacity in A549 cells.</summary>
    <dc:date>2025-07-21T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Estudo da interferência do álcool perílico na atividade antitumoral da doxorrubicina em camundongos com sarcoma 180</title>
    <link rel="alternate" href="https://ri.ufs.br/jspui/handle/riufs/24694" />
    <author>
      <name>Lima, Lorrane Nere de</name>
    </author>
    <id>https://ri.ufs.br/jspui/handle/riufs/24694</id>
    <updated>2026-03-04T13:19:16Z</updated>
    <published>2026-01-30T00:00:00Z</published>
    <summary type="text">Título: Estudo da interferência do álcool perílico na atividade antitumoral da doxorrubicina em camundongos com sarcoma 180
Autor(es): Lima, Lorrane Nere de
Abstract: The therapeutic management of sarcomas remains a clinical challenge due to the high heterogeneity and&#xD;
complexity of these neoplasms. Therefore, the combination of antineoplastic agents is&#xD;
fundamental to increase antitumor efficacy and mitigate toxic effects. Doxorubicin, the&#xD;
drug of choice in the treatment of sarcomas, has broad clinical efficacy; however, it can&#xD;
cause a risk of cardiotoxicity, as well as hepatotoxicity and hematological toxicity&#xD;
mediated by oxidative stress and inflammation. Perillyl alcohol, a monoterpene with&#xD;
anticancer, antioxidant, and anti-inflammatory properties, could potentiate the antitumor&#xD;
effect of doxorubicin and attenuate its toxic effects. Therefore, the aim of this study was to&#xD;
evaluate the interference of perillyl alcohol on the antitumor activity of doxorubicin in mice&#xD;
with sarcoma 180. For this, 56 male Swiss mice, transplanted with Sarcoma 180 cells, were&#xD;
distributed into 8 groups (n=7), namely: Saline [tween 80 0.2%, orally, on consecutive days&#xD;
+ sodium chloride 0.9%, on alternate days, intraperitoneally (ip.)]; DOX (doxorubicin 2&#xD;
mg/kg, on alternate days, i.p.); POH 50 (perillyl alcohol 50 mg/kg/day, orally), POH 100&#xD;
(perillyl alcohol 100 mg/kg/day, orally), POH 200 (perillyl alcohol 200 mg/kg/day, orally),&#xD;
POH 50 + DOX (perillyl alcohol 50 mg/kg/day, orally + doxorubicin 2 mg/kg, every other&#xD;
day, intraperitoneally), POH 100 + DOX (perillyl alcohol 100 mg/kg/day, orally +&#xD;
doxorubicin 2 mg/kg, every other day, intraperitoneally), and POH 200 + DOX (perillyl&#xD;
alcohol 200 mg/kg/day, orally + doxorubicin 2 mg/kg, every other day, intraperitoneally).&#xD;
These treatments were administered for 9 days. Following the experiment, parameters of&#xD;
tumor inhibition, body and organ mass, biochemical markers of cardiac and hepatic injury,&#xD;
oxidative stress in cardiac and hepatic tissue – through levels of malondialdehyde (MDA),&#xD;
total sulfhydryls, and activity of glutathione peroxidase (GPX) and superoxide dismutase&#xD;
(SOD) – and hematological analysis were evaluated. Data were processed using the&#xD;
Shapiro-Wilk test, analysis of variance (one-way or two-way), and Tukey's post-hoc test.&#xD;
The results showed that the combined treatment did not present a significant antitumor&#xD;
effect. In toxicological parameters, the combined treatment led to loss of body mass and&#xD;
heart and liver mass, as well as elevation of levels of biochemical markers of cardiac and&#xD;
hepatic injury, especially in the POH 50 + DOX and POH 100 + DOX groups. In oxidative&#xD;
stress of cardiac tissue, the POH 100 + DOX and POH 200 + DOX groups showed elevated&#xD;
MDA levels, with increased SOD activity in the latter group. In liver tissue, MDA levels&#xD;
decreased in both combined treatment groups, and GPX activity increased. Hematological&#xD;
analysis showed that the alterations induced by doxorubicin persisted in the combined&#xD;
treatment. Therefore, perillyl alcohol combined with doxorubicin did not show promise in the treatment of sarcoma 180.</summary>
    <dc:date>2026-01-30T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Alterações comportamentais e fisiológicas após exposição crônica de cletodim em ratos</title>
    <link rel="alternate" href="https://ri.ufs.br/jspui/handle/riufs/24672" />
    <author>
      <name>Barbosa, Abraão de Jesus</name>
    </author>
    <id>https://ri.ufs.br/jspui/handle/riufs/24672</id>
    <updated>2026-02-26T19:28:40Z</updated>
    <published>2026-02-09T00:00:00Z</published>
    <summary type="text">Título: Alterações comportamentais e fisiológicas após exposição crônica de cletodim em ratos
Autor(es): Barbosa, Abraão de Jesus
Abstract: Clethodim (CL) is a selective herbicide belonging to the oxime-cyclohexanedione chemical&#xD;
group, whose mechanism of action involves the inhibition of acetyl coenzyme A. It is widely&#xD;
used to combat plants that are resistant to glyphosate. Due to the scarcity of studies in the&#xD;
literature on the impacts of this compound on human or animal health, studies seeking to assess&#xD;
its toxicity in non-target organisms are necessary. The objective of this study was to evaluate&#xD;
behavioral and physiological changes after repeated exposure to CL in rats. As materials and&#xD;
methods, after obtaining approval from the Animal Use Ethics Committee of the Federal&#xD;
University of Sergipe (CEUA/UFS) under protocol no. 5228100323, 30 adult male rats aged 6-&#xD;
8 months (350-500 g) of the Wistar strain were used. The animals were divided into four groups&#xD;
with seven to eight animals per group, according to the concentration of the compound: control&#xD;
(CTL-0.9% saline solution), CL at concentrations of 0.06% (CL-0.06), 0.3% (CL-0.3), and&#xD;
0.6% (CL-0.6). Twenty-five nebulization exposures were performed (one every 48 hours,&#xD;
lasting 10 minutes each) with saline solution or CL according to the experimental group.&#xD;
Throughout the experiment, behavioral tests were performed, namely: catalepsy (every 48&#xD;
hours), open field (OF - days 0 and 38), novel object recognition (NOR - day 12), spontaneous&#xD;
alternation (SA - day 16), and forced swim test (FST - day 25). In addition, assessments of body&#xD;
mass (every 4 days), food intake (day 44), glycemic tolerance (day 48), and organ mass&#xD;
measurement and brain removal after perfusion (day 50) were performed. The brains were then&#xD;
processed to assess the immunoreactivity of Brain-Derived Neurotrophic Factor (BDNF), cFos, and Choline-O-Acetyl-Transferase (ChAT) proteins. Our results showed that the CL-0.06&#xD;
group had a shorter time in the catalepsy test and lower spleen mass; in the CL-0.6 group, we&#xD;
observed a shorter time in the center in the CA and impairment in working memory in the AE,&#xD;
but not in the RO, increased body variation, and lower glycemic peak in the glucose tolerance&#xD;
test; in all concentrations, we observed lower food consumption and a higher number of&#xD;
immobility events with longer immobility time in the TNF. Regarding neurochemical&#xD;
assessments, lower immunoreactivity for BDNF and c-Fos was identified in hippocampal&#xD;
regions in the CL-0.06 and CL-0.3 groups, with no changes in ChAT expression in cholinergic&#xD;
areas. In conclusion, our study demonstrated that exposure to CL according to concentration&#xD;
was capable of promoting anxiety- and depression-like behavior, memory deficits, increased&#xD;
body mass, and decreased hippocampal activity.</summary>
    <dc:date>2026-02-09T00:00:00Z</dc:date>
  </entry>
</feed>

